Clinical trialNCT00679354CompletedPhase 2Interventional

Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy

SponsorNational Cancer Institute (NCI)Enrollment30Childhood High-grade Cerebellar AstrocytomaChildhood High-grade Cerebral AstrocytomaRecurrent Childhood Anaplastic AstrocytomaRecurrent Childhood Anaplastic OligoastrocytomaRecurrent Childhood Anaplastic OligodendrogliomaRecurrent Childhood Brain Tumor+4 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial studies how well cilengitide works in treating younger patients with recurrent or progressive high-grade glioma that has not responded to standard therapy. Cilengitide may stop the growth of tumor cells by blocking blood flow to the tumor.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Tobey MacDonald
Children's Oncology Group
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

20 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Cancercare Manitoba
Winnipeg, Manitoba, Canada

United States

Kaiser Permanente-Oakland
Oakland, California, United States
University of California San Francisco Medical Center-Parnassus
San Francisco, California, United States
Lombardi Comprehensive Cancer Center at Georgetown University
Washington D.C., District of Columbia, United States
Lurie Children'S Hospital-Chicago
Chicago, Illinois, United States
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
Wayne State University/karmanos Cancer Institute
Detroit, Michigan, United States
Newark Beth Israel Medical Center
Newark, New Jersey, United States
New York University Langone Medical Center
New York, New York, United States
Montefiore Medical Center
The Bronx, New York, United States
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
Children'S Hospital Medical Center of Akron
Akron, Ohio, United States
Nationwide Children'S Hospital
Columbus, Ohio, United States
Oregon Health and Science University
Portland, Oregon, United States
Children'S Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Palmetto Health Richland
Columbia, South Carolina, United States
T C Thompson Children'S Hospital
Chattanooga, Tennessee, United States
St. Jude Children'S Research Hospital
Memphis, Tennessee, United States
Seattle Children'S Hospital
Seattle, Washington, United States
Midwest Children'S Cancer Center
Milwaukee, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Cilengitide

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Jun 2008
Primary completion: 31 Oct 2010
Completion: 31 Jul 2011
Last update posted: 1 Aug 2018
Registered enrollment: 30
Registry id: NCT00679354

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.